Friday 6 November 2026
Export ACAD’s income statement to Excel — free account
ACADIA Pharmaceuticals Inc.
ACAD Healthcare Biotechnology
ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024.
- Revenue
- +22.9%
- EPS
- −27.9%
- Free cash flow
- +141.2%
Quarter to September 2026, against a year earlier
21.23
0.01
−0.05%
Follow ACAD
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 5 | 5 | 6 |
+8 more TTM periods Free account |
| 31.43% | 35.74% | 37.32% | 39.89% | ||
| 23.18% | 25.64% | 27.44% | 28.42% | ||
ROIC |
18.60% | 15.42% | 12.75% | 16.07% | |
Return on Tangible Assets |
37.95% | 43.23% | 46.66% | 49.34% | |
Average Days of Receivables |
54.13 | 53.32 | 49.45 | 50.49 | |
Free Cash Flow per Share |
0.48 | 0.85 | 0.67 | 0.62 | |
Free Cash Flow |
81.99 | 145.63 | 113.59 | 104.69 | |
Capital Expenditures |
(15.55) | (14.69) | (9.90) | (5.14) | |
| Other line items | |||||
Cash ROIC |
3.47% | 6.43% | 5.41% | 5.11% | |
Accounts Receivable Turnover |
7.57 | 7.96 | 8.36 | 8.47 | |
Accounts Payable Turnover |
6.01 | 3.12 | 6.16 | 6.57 | |
Inventory Turnover |
3.29 | 3.45 | 3.43 | 3.14 | |
Average Days of Payables |
52.09 | 161.09 | 47.86 | 44.72 | |
Days of Inventory on Hand |
128.75 | 117.01 | 123.39 | 142.19 | |
Tax Rate |
1.30 | 2.14 | 2.26 | 1.81 | |
Research and Development Expense of Revenue |
26.57% | 29.07% | 29.89% | 30.69% | |
Selling, General and Administrative Expense of Revenue |
53.74% | 54.48% | 54.19% | 51.23% | |
Share Based Compensation of Revenue |
5.18% | 5.10% | 5.06% | 4.87% | |
Operating CF/Net income |
0.27 | 0.42 | 0.33 | 0.28 | |
Depreciation/Fixed assets |
0.62 | 0.57 | 0.55 | 0.84 | |
Capex/Depreciation |
(1.36) | (1.51) | (1.23) | (0.81) | |
Revenue per Share |
6.97 | 6.64 | 6.42 | 6.36 | |
Operating CF per Share |
0.57 | 0.93 | 0.72 | 0.65 | |
Capex per Share |
(0.09) | (0.09) | (0.06) | (0.03) | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026